Delcath Systems to Present at Jefferies Virtual Healthcare Conference
26 May 2021 - 11:00PM
Delcath Systems, Inc. (Nasdaq:
DCTH), an
interventional oncology company focused on the treatment of rare
primary and metastatic cancers of the liver, announced today that
management will present at:
- Jefferies Virtual
Healthcare Conference on June 3, 2021 at 4:00 PM (ET)
-
https://wsw.com/webcast/jeff174/dcth/1835973
For more information or to schedule a one-on-one
meeting with management, please contact your conference
representative or James@HaydenIR.com.
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional
oncology company focused on the treatment of primary and metastatic
liver cancers. Our investigational product, HEPZATO KIT (melphalan
hydrochloride for injection/hepatic delivery system), is designed
to administer high-dose chemotherapy to the liver while controlling
systemic exposure and associated side effects. HEPZATO KIT has not
been approved by the U.S. Food & Drug Administration (FDA) for
sale in the U.S. In Europe, our system is marketed under the trade
name Delcath CHEMOSAT® Hepatic Delivery System for Melphalan
(CHEMOSAT) and has been CE Marked and used at major medical centers
to treat a wide range of cancers of the liver. CHEMOSAT is being
marketed under an exclusive licensing agreement with medac GmbH, a
privately held multi-national pharmaceutical company headquartered
in Germany that specializes in the treatment and diagnosis of
oncological, urological and autoimmune diseases.
Contact:
Delcath Investor Relations
Email: investorrelations@delcath.com
Hayden IR
James
Carbonara(646)-755-7412james@haydenir.com
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
From Jul 2023 to Jul 2024